Saturday, 14 November 2026European Markets
ExploreSearch
vianews.eu
stockMarket

CARPINIENNE PART. Stock Drops By 25% In The Last 10 Sessions

Automated market report from our archive (2020–2024), published before source-traceability. How we work

Loading stream...

(vianews) - shares of carpinienne part. (cac 40: carp.pa) dropped by a staggering 25.16% in 10 sessions from 7.75 € to 5.80 € at 19:55 est on wednesday, after five successive sessions in a row of losses. cac 40 is dropping 0.18% to 7,119.83 €, after two consecutive sessions in a row of losses.

about carpinienne part.

carpinienne de participations operates as an investment company. it holds 5.14% interests in foncière euris, which has a property portfolio that primarily consists of shopping malls. the company was founded in 1968 and is headquartered in paris, france. carpinienne de participations is a subsidiary of finatis société anonyme.

earnings per share

as for profitability, carpinienne part. has a trailing twelve months eps of -1.34 €.

more news about carpinienne part. (carp.pa).

Categories

stockMarket

Tags

CARPINIENNE PART.Stock PricePrice DownMarket Session NowStock Price DownStock Market NowMarket SessionStock MarketStockCARP.PA
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,580 source documents archived
Query this data → isubstrate.com